Interactions between Trospium and Valacyclovir

Trospium has a moderate potential interaction with Alcoholism.

The use of alcohol may enhance the drowsiness caused by anticholinergic agents. It is recommended that alcohol should not be consumed within 2 hours of trospium administration. Caution should be exercised when using this agent in alcoholic patients.

valACYclovir has a moderate potential interaction with Bone Marrow Transplantation.

Thrombotic thrombocytopenic purpura/hemolytic uremia syndrome (TTP/HUS), in some cases resulting in death, has been reported in patients with advanced HIV-1 disease, in allogeneic bone marrow transplant recipients, and in renal transplant recipients during clinical trials of valacyclovir at doses of 8 g/day. Therapy with valacyclovir should be discontinued immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS develop.

valACYclovir has a moderate potential interaction with Dehydration.

Valacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism; acyclovir is primarily eliminated by the kidney. Cases of acute renal failure have been reported in patients without adequate hydration. Acyclovir may precipitate in renal tubules when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Adequate hydration should be maintained for all patients. If acute renal failure and anuria occur, patients may benefit from hemodialysis until renal function is restored.

Trospium has a major potential interaction with Gastrointestinal Obstruction.

The use of trospium is contraindicated in patients with gastric retention. Trospium reduces the tonus of smooth muscle and may decrease gastrointestinal motility, hence it should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. Caution should be exercised when using this drug in patients with gastrointestinal obstructive disorders as it increases the risk of gastric retention.

Trospium has a major potential interaction with Glaucoma, Narrow Angle.

The use of trospium is contraindicated in patients with uncontrolled narrow-angle glaucoma. In those patients being treated for narrow-angle glaucoma, trospium should only be used if the potential benefits outweigh the risks and in that circumstance only with careful monitoring.

valACYclovir has a moderate potential interaction with Hemodialysis.

Valacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. About one-third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session. The recommended dose of valacyclovir should be administered after hemodialysis.

valACYclovir has a moderate potential interaction with Immunodeficiency.

Thrombotic thrombocytopenic purpura/hemolytic uremia syndrome (TTP/HUS), in some cases resulting in death, has been reported in patients with advanced HIV-1 disease, in allogeneic bone marrow transplant recipients, and in renal transplant recipients during clinical trials of valacyclovir at doses of 8 g/day. Therapy with valacyclovir should be discontinued immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS develop.

Trospium has a moderate potential interaction with Liver Disease.

Caution is advised when administering trospium to patients with moderate to severe hepatic impairment. There is no information regarding the effect of severe hepatic impairment on exposure to trospium.

Trospium has a major potential interaction with Myasthenia Gravis.

The use of trospium is contraindicated in patients with gastric retention. Trospium reduces the tonus of smooth muscle and may decrease gastrointestinal motility, hence it should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. Caution should be exercised when using this drug in patients with gastrointestinal obstructive disorders as it increases the risk of gastric retention.

valACYclovir has a moderate potential interaction with Neutropenia.

Thrombotic thrombocytopenic purpura/hemolytic uremia syndrome (TTP/HUS), in some cases resulting in death, has been reported in patients with advanced HIV-1 disease, in allogeneic bone marrow transplant recipients, and in renal transplant recipients during clinical trials of valacyclovir at doses of 8 g/day. Therapy with valacyclovir should be discontinued immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS develop.

valACYclovir has a moderate potential interaction with Organ Transplant.

Thrombotic thrombocytopenic purpura/hemolytic uremia syndrome (TTP/HUS), in some cases resulting in death, has been reported in patients with advanced HIV-1 disease, in allogeneic bone marrow transplant recipients, and in renal transplant recipients during clinical trials of valacyclovir at doses of 8 g/day. Therapy with valacyclovir should be discontinued immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS develop.

Trospium has a moderate potential interaction with Renal Dysfunction.

Trospium is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. A reduced dose is recommended in patients with severe renal impairment (CrCl less than 30 mL/minute). The pharmacokinetics of trospium have not been studied in patients with CrCl 30 to 80 mL/min.

valACYclovir has a moderate potential interaction with Renal Dysfunction.

Valacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism; acyclovir is primarily eliminated by the kidney. Cases of acute renal failure and CNS side effects (including agitation, hallucinations, confusion, delirium, seizures, and encephalopathy) have been reported in patients with preexisting renal disease who received higher-than-recommended doses of valacyclovir for their level of renal function. Cases of acute renal failure have also been reported in patients receiving other nephrotoxic agents. Therapy with valacyclovir should be administered cautiously in elderly patients (with or without renal dysfunction) and patients receiving other nephrotoxic agents. Dosage reductions are recommended in patients with renal dysfunction. If acute renal failure and anuria occur, patients may benefit from hemodialysis until renal function is restored; valacyclovir should be discontinued if CNS side effects develop.

Trospium has a major potential interaction with Ulcerative Colitis.

The use of trospium is contraindicated in patients with gastric retention. Trospium reduces the tonus of smooth muscle and may decrease gastrointestinal motility, hence it should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. Caution should be exercised when using this drug in patients with gastrointestinal obstructive disorders as it increases the risk of gastric retention.

Trospium has a major potential interaction with Urinary Retention.

Use of trospium is contraindicated in patients with urinary retention. Administer trospium with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.